Acumen reiterates November 2026 ALTITUDE-AD readout for Alzheimer's drug sabirnetug

Acumen Pharmaceuticals reported third quarter 2026 results on October 26, 2026, and said it expects to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in November 2026¹.

ALTITUDE-AD is a 3-arm Phase 2 study investigating sabirnetug in 542 participants, with 180 per arm, testing two active doses of 35 mg/kg and 50 mg/kg given intravenously every four weeks against placebo over an 18-month double-blinded period¹. The company said topline results are expected to include the iADRS primary efficacy endpoint, key secondary endpoints such as CDR-SB, safety measures including ARIA rates, and key biomarkers¹.

On the pipeline side, Acumen said it is targeting an IND filing for the lead clinical candidate in its Enhanced Brain Delivery (EBD) program for mid-2027¹. The company described the EBD effort as a collaboration with JCR Pharmaceuticals to develop an Enhanced Brain Delivery therapy for Alzheimer's disease using a transferrin-receptor-targeting blood-brain barrier-penetrating technology¹. Acumen also said it is testing a subcutaneous version of sabirnetug built on Halozyme's ENHANZE drug delivery platform¹.

On financing, the company reported cash, cash equivalents and marketable securities of $78.6 million as of September 30, 2026, compared with $110.2 million as of June 30, 2026¹. Acumen said this balance is expected to support current clinical and operational activities into early 2027¹.

Sabirnetug (ACU193) has received Fast Track designation from the FDA for early Alzheimer's disease and is being evaluated in the ongoing Phase 2 study¹. The ALTITUDE-AD trial, initiated in 2024, is enrolling 542 individuals with early Alzheimer's disease across sites in the United States, Canada, the European Union and the United Kingdom¹.